The stock's rise snapped a three-day losing streak.

Shares of Bio-Techne Corp. TECH shed 2.18% to $57.35 Tuesday, on what proved to be an all-around mixed trading session for ...

Shareholders of Bio-Techne would probably like to forget the past six months even happened. The stock has dropped 26.9% and ...

Bio-Techne (TECH) announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics, or ACD, ...

Bio-Techne Corporation TECH recently opened a new Customer Experience Centre in Düsseldorf, Germany, to serve customers across the Europe, Middle East and Africa (“EMEA”) region. The facility's ...

Learn more about whether Repligen Corporation or Bio-Techne Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Dr. Gregory Bean, Associate Professor of Pathology at Stanford University, will describe the direct detection of mRNA from CRTC1/3::MAML2 translocations, as alternatives to MAML2 FISH, in the ...

Corporation announced further advancements in its ongoing strategy to bring translational discoveries to patient care by ...

Bio-Techne (NASDAQ:TECH – Get Free Report) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Tuesday. A number of other ...

Equities research analysts at Evercore ISI assumed coverage on shares of Bio-Techne (NASDAQ:TECH – Get Free Report) in a ...

In the preceding three months, 6 analysts have released ratings for Bio-Techne (NASDAQ:TECH), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates ...

Bio-Techne Corporation TECH recently opened a new Customer Experience Centre in Düsseldorf, Germany, to serve customers across the Europe, Middle East and Africa (“EMEA”) region. The facility ...